Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Insight, Epidemiology And Market Forecast - 2034
Description
Key Highlights
DelveInsight research indicates that in 2024, there were more than 1 million total diagnosed prevalent cases of Interstitial Lung Disease (ILD) across the 7MM, which are expected to increase by 2034.
In the US, diagnosed prevalent cases of PH-ILD exceeded 80,000 in 2024, with numbers expected to climb further by 2034, reflecting a growing disease burden.
ILD includes various subtypes such as idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), sarcoidosis, connective tissue disease (CTD)-related ILD, combined pulmonary fibrosis and emphysema (CPFE), hypersensitivity pneumonitis, and others. In the US, diagnosed prevalent cases of IPF in ILD were nearly 11,000 in 2024, with numbers projected to rise further by 2034.
The total market size of PH-ILD in the 7MM was approximately USD 3 billion in 2024 and is projected to increase during the forecast period (2025–2034).
A key strength in the PH-ILD landscape is the recent therapeutic progress, marked by the approval of YUTREPIA in 2025, signaling continued advancement in the clinical space. TYVASO, available since 2021, has established a treatment foundation, and the addition of YUTREPIA reflects growing momentum in addressing this complex condition.
Addressing this unmet need, several emerging therapies such as Treprostinil liposomal (L606), Treprostinil Palmitil Inhalation Powder (TPIP), Mosliciguat, H1614 (HB-1614), and others are in development, aiming to expand the limited treatment arsenal for PH-ILD with more targeted and potentially disease-modifying options.
In January 2025, at the 43rd Annual JP Morgan Healthcare Conference, Liquidia Corporation highlighted treprostinil (L606) for its twice-daily dosing, improved tolerability, and rapid delivery through a next-generation, breath-actuated handheld nebulizer equipped with smart technology.
Liquidia Corporation, Pharmosa BioPharm, United Therapeutics, and other key players are advancing novel therapies through clinical development, signaling strong momentum in the PH-ILD space. Their efforts are poised to reshape the treatment landscape, addressing critical gaps in care and improving long-term outcomes for patients.
DelveInsight’s “Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) – Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of PH-ILD, historical and forecasted epidemiology, as well as the PH-ILD market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The PH-ILD market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM PH-ILD market size from 2020 to 2034. The report also covers PH-ILD treatment practices/algorithm PH-ILD and unmet medical needs to curate the best opportunities and assess the market’s potential.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Understanding and Treatment Algorithm
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Overview
PH-ILD is a chronic and progressive condition that arises as a complication of various ILDs, such as IPF, CTD, and hypersensitivity pneumonitis. It is characterized by increased pressure in the pulmonary arteries due to lung scarring and vascular remodeling, which places significant strain on the heart and lungs. Patients often experience worsening shortness of breath, fatigue, and reduced exercise capacity, with symptom PH-ILD gradually limiting daily activities and overall quality of life. Without timely management, the disease can progress to right heart failure and carries a high risk of morbidity and mortality. As one of the most serious complications of ILD, PH-ILD represents a critical area for early detection, routine screening in high-risk populations, and the development of more effective, personalized treatment strategies.
Further details related to country-based variations are provided in the report…
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Diagnosis
Diagnosing PH-ILD is challenging due to overlapping symptom of PH-ILD with the underlying ILD. Suspicion should arise in ILD patients with unexplained worsening dyspnea or reduced exercise capacity. Key tools include echocardiography for initial screening and pulmonary function tests showing a disproportionate drop in Diffusing Capacity of the Lung for Carbon Monoxide (DLCO). High-resolution Computed Tomography (CT) aids in assessing lung fibrosis, while right heart catheterization remains the gold standard for confirming pulmonary hypertension. Early, accurate diagnosis through routine monitoring in high-risk ILD patients is crucial for timely intervention and improved outcomes.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Treatment
Treatment of PH-ILD focuses on managing symptoms, slowing disease progression, and improving quality of life. As there is no cure, a multidisciplinary approach is essential. Optimizing management of the underlying ILD remains the foundation, while supportive care including oxygen therapy, pulmonary rehabilitation, and symptom control is key to maintaining function. In select cases, pulmonary vasodilators may be used to improve exercise capacity, though their benefit varies based on disease severity and patient profile. Early identification, regular monitoring, and personalized care strategies are critical to delay progression. In advanced stages, lung transplantation may be considered. Continued research is driving the development of more targeted, lung-specific therapies to address the high unmet need in PH-ILD.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology
As the market is derived using a patient-based model, the PH-ILD epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of ILD, type-specific diagnosed prevalent cases of ILD, type-specific diagnosed prevalent cases of PH-ILD, total diagnosed prevalent cases of PH-ILD, and gender-specific diagnosed prevalent cases of PH-ILD in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
In 2024, in the US, diagnosed prevalence of PH-ILD showed a slightly higher burden in males, with approximately 42,000 cases compared to 39,000 in females. This gender gap is expected to widen by 2034, highlighting potential differences in disease susceptibility or progression.
In 2024, an estimated 69,000 people in the EU4 and the UK were diagnosed with PH-ILD, underscoring a substantial and growing regional disease burden.
In France, CTD linked with PH-ILD had the highest diagnosed prevalence, with nearly 4,000 cases in 2024, while hypersensitivity pneumonitis reported the lowest burden, with just over 500 cases.
In Japan, over 28,000 diagnosed prevalent cases of PH-ILD were reported in 2024, with the numbers projected to increase by 2034, indicating a rising disease burden.
In 2024, IPF accounted for the largest share of PH-ILD cases in Japan at 21%, while hypersensitivity pneumonitis represented just 1%, underscoring notable variation in subtype distribution and the need for tailored diagnostic and treatment strategies.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Drug Chapters
PH-ILD Marketed Drugs
YUTREPIA (Treprostinil): Liquidia Corporation
YUTREPIA is a dry powder inhalation formulation of treprostinil sodium, a prostacyclin mimetic designed for the treatment of PAH. Delivered through a single-use, handheld inhaler, each capsule contains treprostinil sodium blended with carefully selected excipients L-leucine, polysorbate 80, sodium chloride, sodium citrate, and trehalose.
In May 2025, YUTREPIA (treprostinil) received full Food and Drug Administration (FDA) approval for improving exercise capacity in adults with Pulmonary Arterial Hypertension (PAH) and PH-ILD. As the first dry powder prostacyclin using Liquidia’s PRINT technology, it offers deep lung delivery with improved usability and adherence potential.
In August 2024, Liquidia received tentative FDA approval for YUTREPIA, its inhaled dry powder treprostinil for PAH and PH-ILD, with full commercialization allowed after regulatory exclusivity ends in May 2025. The NDA was filed via the 505(b) (2) pathway referencing nebulized TYVASO.
In June 2024, the US District Court denied United Therapeutics’ motion to block YUTREPIA’s launch, removing a key legal hurdle and reinforcing FDA’s ability to advance Liquidia’s amended NDA, strengthening its regulatory and commercial stance.
TYVASO/TYVASO DPI/TREPROST (treprostinil): United Therapeutics
TYVASO and TYVASO DPI (treprostinil) are approved inhaled therapies for PAH (Group 1) and PH-ILD (Group 3), helping improve exercise capacity in adults, though effects may diminish after ~4 hours. In Japan, treprostinil is available as TREPROST, but it has been withdrawn from European markets.
In September 2024, Mochida Pharmaceutical reported that treprostinil had been designated as an Orphan Drug Designation (ODD) from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of PH-ILD, including combined pulmonary fibrosis and emphysema (CPFE). Mochida obtained distribution rights from United Therapeutics in 2017.
In May 2022, the US FDA approved TYVASO DPI inhalation powder, marking the first dry powder inhaler formulation of treprostinil for both PAH (PAH; WHO Group 1) and PH-ILD (PH-ILD; WHO Group 3).
In January 2021, United Therapeutics reported the FDA approval and commercial launch of TYVASO (treprostinil) inhalation aerosol. It is indicated to enhance exercise capacity in patients with PAH and PH-ILD.
PH-ILD Emerging Drugs
Treprostinil liposomal (L606): Pharmosa Biopharm/Liquidia Corporation
L606 is a liposomal formulation of treprostinil, with liposome particle sizes ranging from 110–140 nm, suspended in a sodium citrate–bicarbonate buffer. This advanced formulation is engineered to enhance drug stability and prolong systemic circulation by protecting treprostinil from rapid degradation and clearance. The liposomal encapsulation enables a sustained pulmonary release, allowing for more consistent drug exposure over time, while minimizing peaks and troughs that may lead to side effects. The citrate–bicarbonate buffer not only helps maintain an optimal pH for lung tolerability but also supports better drug solubility and absorption.
In October 2024, Liquidia Corporation and Pharmosa Biopharm (Pharmosa) reported that they have amended the current exclusive licensing agreement for the development and commercialization of L606, an inhaled, sustained-release formulation of treprostinil currently being evaluated in a clinical trial for the treatment of PAH and PH-ILD.
Treprostinil Palmitil Inhalation Powder (TPIP): Insmed
TPIP is a next-generation, once-daily dry powder formulation of a treprostinil prodrug, delivered via a convenient capsule-based inhaler. Engineered by Insmed, TPIP features a 16-carbon ester-linked modification for extended activity and is being developed for PAH, PH-ILD, and other severe pulmonary conditions. With promising Phase IIb results, a pivotal Phase III trial is expected to launch in the second half of 2025, marking a major step toward transforming treatment for rare lung diseases.
Mosliciguat: Roivant Sciences/Pulmovant
Mosliciguat (BAY 1237592) is a first-in-class sGC activator being developed for PH-ILD, offering a nitric oxide–independent mechanism that promotes vasodilation even under hypoxic and oxidative stress conditions. It may also provide anti-inflammatory and anti-fibrotic benefits. Phase II topline results are expected in H2 2026.
In June 2025, Pulmovant reported the publication of Phase I pharmacokinetic data in healthy male volunteers following administration of mosliciguat.
In September 2024, Pulmovant, a Roivant company, reported Phase Ib ATMOS1 study data during the European Respiratory Society (ERS) Congress.
In September 2024, Roivant formed Pulmovant to acquire exclusive global rights from Bayer to develop and commercialize mosliciguat, with Bayer receiving USD 14 million upfront and up to USD 280 million in milestones and tiered royalties. Mosliciguat is being investigated as a once-daily inhaled therapy for PH-ILD.
Drug Class Insights
The PH-ILD treatment landscape is shifting from supportive care to targeted, disease-modifying approaches that address vascular remodeling, fibrosis, and inflammation. Traditional strategies, including ILD management and lung transplantation, offer limited impact on long-term outcomes, highlighting the need for more effective therapies.
New drug classes with lung-targeted mechanisms are advancing PH-ILD treatment. Inhaled prostacyclins like treprostinil have enhanced exercise capacity, setting the stage for next-generation agents such as Mosliciguat (sGC activator), H1614 (HA synthesis inhibitor), and RT234 (inhaled PDE5 inhibitor). These candidates aim to deliver broader benefits—beyond vasodilation—by incorporating anti-fibrotic and anti-inflammatory effects, marking a shift toward disease-modifying approaches.
Continued in report…
Market Outlook
The market for PH-ILD is undergoing significant transformation, driven by growing disease recognition, evolving clinical strategies, and novel therapeutic development. PH-ILD is the most common form of Group 3 pulmonary hypertension and represents a serious complication of ILD, contributing to cardiopulmonary disability, right heart dysfunction, and increased mortality. Despite supportive treatments such as oxygen therapy and corticosteroids to manage acute exacerbations, current standards offer limited long-term benefit and do not halt disease progression.
The introduction of inhaled prostacyclin therapies like TYVASO/ TYVASO DPI, and YUTREPIA—the only agents specifically approved for PH-ILD—has reshaped the therapeutic landscape. These targeted treatments have helped reduce pulmonary vascular resistance (PVR) and improve functional capacity in patients with various for PH-ILD of ILD, including IPF and connective tissue disease-associated ILD. The success of these products has also set the stage for expanding global access and innovation in delivery methods, such as dry powder inhalers and liposomal formulations that enhance patient adherence and convenience.
Real-world studies across the US, Europe, and Japan underscore the high clinical and economic burden of PH-ILD, revealing increased hospitalizations, ICU admissions, and variability in diagnostic and therapeutic approaches. These findings point to underdiagnoses, inconsistent care patterns, and widespread off-label use of pulmonary vasodilators, particularly PDE5 inhibitors, in regions lacking approved therapies. They also emphasize the urgent need for standardized, evidence-based guidelines and more effective, accessible treatments.
The pipeline for PH-ILD is rich with candidates targeting not just vasodilation, but also fibrosis and vascular remodeling—key PH-ILD driving disease progression. Inhaled agents like TPIP, mosliciguat, seralutinib, and RT234, and oral therapies like H1614, represent next-generation approaches aiming to offer improved efficacy, safety, and disease-modifying potential. Many of these are in Phase II or III development and could transform management by offering alternatives to current standards or enhancing outcomes through combination strategies.
With rising transplant volumes, increased disease awareness, and strong momentum in clinical research, the PH-ILD therapeutics market is poised for sustained growth from 2025 to 2034. As more targeted agents gain approval and are integrated into practice, PH-ILD management is expected to shift toward a more personalized, mechanism-driven approach ultimately improving prognosis and quality of life for patients facing this progressive condition.
Companies like United Therapeutics (TYVASO/TYVASO DPI/ TREPROST), Liquidia Corporation (YUTREPIA), Bayer (Mosliciguat), Halo Biosciences (H1614), and other are actively advancing therapies for PH-ILD, with assets spanning late-stage (Phase III) to early-stage (Phase I) development. These program PH-ILD reflect a strategic industry focus on inhaled and lung-specific PH-ILD targeting vasodilation, fibrosis, and inflammation—key drivers of disease progression in PH-ILD.
The total market size of PH-ILD in the 7MM was approximately USD 3 billion in 2024 and is projected to increase during the forecast period (2025–2034).
The market size for PH-ILD in the US was approximately USD 2 billion in 2024 and is anticipated to increase due to the launch of emerging therapies.
The total market size of EU4 and the UK was calculated to be approximately USD 480 million in 2024, which was nearly 23% of the total market revenue for the 7MM and is expected to increase by 2034.
In 2024, the UK dominated the European market, generating around USD 120 million. Germany followed closely with approximately USD 100 million, while Spain recorded around USD 70 million.
In 2024, the total market size of PH-ILD was approximately USD 285 million in Japan, which is anticipated to increase during the forecast period (2025-2034).
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to be launched in the market during study period 2020–2034.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.
Pipeline development activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for PH-ILD.
KOL Views
To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on PH-ILD evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and others.
DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the Baylor College of Medicine and Methodist Hospital, US; University of Minnesota, US; University of Freiburg, Germany; Hôpital St Louis, France; University of Siena, Italy; University of Valencia, Spain; University Forvie Site, UK; Jichi Medical University, Japan; and Chiba University, Japan; among others, were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or PH-ILD market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Physician’s View
KOLs in the US highlight a critical gap in PH-ILD care, noting that despite rising prevalence, timely diagnosis remains low due to overlapping symptoms of PH-ILD with other ILDs. This diagnostic delay often results in patients missing the optimal treatment window for slowing disease progression.
According to European KOLs, current treatment options for PH-ILD remain largely supportive, with few therapies targeting the underlying vascular remodeling and fibrotic processes. This underscores an urgent need for more effective, disease-modifying interventions.
Japanese KOLs stress the growing burden of PH-ILD, particularly among aging ILD populations, and emphasize that limited approved therapies fail to address the heterogeneity of the disease. The lack of standardized treatment protocols further contributes to unmet needs in real-world clinical management.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Attribute Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in PH-ILD of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Attribute Analysis analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies’ safety is evaluated wherein the adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials, which directly affects the safety of the molecule in the upcoming trials. It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
US
YUTREPIA: Liquidia Corporation
VOUCHER PROGRAM
The YUTREPIA Voucher Program offers a one-time, 28-day supply of the therapy at no cost to eligible patients, providing a critical opportunity to assess tolerability, adherence, and clinical fit before initiating full treatment. This approach not only reduces financial hesitation at the start of care but also supports informed decision-making for both patients and providers, ultimately promoting sustained engagement with therapy and optimizing long-term treatment outcomes.
Patient eligible
Patients may be eligible for the YUTREPIA Voucher Program if they have been prescribed YUTREPIA for an FDA-approved indication and are 18 years of age or older, or if under 18, are enrolled by their legal guardian(s). This eligibility framework ensures appropriate access while supporting early evaluation of the therapy in alignment with regulatory and clinical standards.
Further details will be provided in the report.
The report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios, PH-ILD making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug PH-ILD, etc.
Scope of the Report
The report covers a segment of key events, an executive summary, and a descriptive overview of PH-ILD, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.
Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will affect the current treatment landscape.
A detailed review of the PH-ILD market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM PH-ILD market.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Report Insights
Patient Population
Therapeutic Approaches
PH-ILD Pipeline Analysis
PH-ILD Market Size and Trends
Existing and Future Market Opportunity
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Report Key Strengths
10 years Forecast
The 7MM Coverage
PH-ILD Epidemiology Segmentation
Key Cross Competition
Attribute analysis
Drugs Uptake and Key Market Forecast Assumptions
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Qualitative Analysis (SWOT and Attribute Analysis)
Key Questions
Market Insights
What was the total market size of PH-ILD, the market size of PH-ILD by therapies, and market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for this growth?
How will Treprostinil liposomal (L606) affect the treatment paradigm of PH-ILD?
Which drug is going to be the largest contributor by 2034?
What are the pricing variations among different geographies for approved and marketed therapies?
How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of PH-ILD? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PH-ILD?
What is the historical and forecasted PH-ILD patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
Out of the countries mentioned above, which country would have the highest diagnosed prevalent PH-ILD population during the forecast period (2025–2034)?
What factors are contributing to the growth of PH-ILD cases?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
What are the current options for the treatment of PH-ILD? What are the current clinical and treatment guidelines for treating PH-ILD?
How many companies are developing therapies for the treatment of PH-ILD?
How many emerging therapies are in the mid-stage and late stage of development for treating PH-ILD?
What are the recent novel therapies, targets, PH-ILD of action, and technologies developed to overcome the limitations of existing therapies?
Patient acceptability in PH-ILD of preferred treatment options as per real-world scenarios?
What is the 7MM historical and forecasted market of PH-ILD?
Reasons to Buy
The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the PH-ILD market.
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
The distribution of historical and current patient share is based on real-world prescription data in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Identifying upcoming solid players in the market will help devise strategies to help get ahead of competitors.
Detailed analysis, ranking of class-wise potential current, and emerging therapies under the attribute analysis section to provide visibility around leading classes.
Highlights of Access and Reimbursement policies for PH-ILD, barriers to accessibility of approved therapy, and patient assistance PH-ILD.
To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
DelveInsight research indicates that in 2024, there were more than 1 million total diagnosed prevalent cases of Interstitial Lung Disease (ILD) across the 7MM, which are expected to increase by 2034.
In the US, diagnosed prevalent cases of PH-ILD exceeded 80,000 in 2024, with numbers expected to climb further by 2034, reflecting a growing disease burden.
ILD includes various subtypes such as idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), sarcoidosis, connective tissue disease (CTD)-related ILD, combined pulmonary fibrosis and emphysema (CPFE), hypersensitivity pneumonitis, and others. In the US, diagnosed prevalent cases of IPF in ILD were nearly 11,000 in 2024, with numbers projected to rise further by 2034.
The total market size of PH-ILD in the 7MM was approximately USD 3 billion in 2024 and is projected to increase during the forecast period (2025–2034).
A key strength in the PH-ILD landscape is the recent therapeutic progress, marked by the approval of YUTREPIA in 2025, signaling continued advancement in the clinical space. TYVASO, available since 2021, has established a treatment foundation, and the addition of YUTREPIA reflects growing momentum in addressing this complex condition.
Addressing this unmet need, several emerging therapies such as Treprostinil liposomal (L606), Treprostinil Palmitil Inhalation Powder (TPIP), Mosliciguat, H1614 (HB-1614), and others are in development, aiming to expand the limited treatment arsenal for PH-ILD with more targeted and potentially disease-modifying options.
In January 2025, at the 43rd Annual JP Morgan Healthcare Conference, Liquidia Corporation highlighted treprostinil (L606) for its twice-daily dosing, improved tolerability, and rapid delivery through a next-generation, breath-actuated handheld nebulizer equipped with smart technology.
Liquidia Corporation, Pharmosa BioPharm, United Therapeutics, and other key players are advancing novel therapies through clinical development, signaling strong momentum in the PH-ILD space. Their efforts are poised to reshape the treatment landscape, addressing critical gaps in care and improving long-term outcomes for patients.
DelveInsight’s “Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) – Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of PH-ILD, historical and forecasted epidemiology, as well as the PH-ILD market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The PH-ILD market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM PH-ILD market size from 2020 to 2034. The report also covers PH-ILD treatment practices/algorithm PH-ILD and unmet medical needs to curate the best opportunities and assess the market’s potential.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Understanding and Treatment Algorithm
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Overview
PH-ILD is a chronic and progressive condition that arises as a complication of various ILDs, such as IPF, CTD, and hypersensitivity pneumonitis. It is characterized by increased pressure in the pulmonary arteries due to lung scarring and vascular remodeling, which places significant strain on the heart and lungs. Patients often experience worsening shortness of breath, fatigue, and reduced exercise capacity, with symptom PH-ILD gradually limiting daily activities and overall quality of life. Without timely management, the disease can progress to right heart failure and carries a high risk of morbidity and mortality. As one of the most serious complications of ILD, PH-ILD represents a critical area for early detection, routine screening in high-risk populations, and the development of more effective, personalized treatment strategies.
Further details related to country-based variations are provided in the report…
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Diagnosis
Diagnosing PH-ILD is challenging due to overlapping symptom of PH-ILD with the underlying ILD. Suspicion should arise in ILD patients with unexplained worsening dyspnea or reduced exercise capacity. Key tools include echocardiography for initial screening and pulmonary function tests showing a disproportionate drop in Diffusing Capacity of the Lung for Carbon Monoxide (DLCO). High-resolution Computed Tomography (CT) aids in assessing lung fibrosis, while right heart catheterization remains the gold standard for confirming pulmonary hypertension. Early, accurate diagnosis through routine monitoring in high-risk ILD patients is crucial for timely intervention and improved outcomes.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Treatment
Treatment of PH-ILD focuses on managing symptoms, slowing disease progression, and improving quality of life. As there is no cure, a multidisciplinary approach is essential. Optimizing management of the underlying ILD remains the foundation, while supportive care including oxygen therapy, pulmonary rehabilitation, and symptom control is key to maintaining function. In select cases, pulmonary vasodilators may be used to improve exercise capacity, though their benefit varies based on disease severity and patient profile. Early identification, regular monitoring, and personalized care strategies are critical to delay progression. In advanced stages, lung transplantation may be considered. Continued research is driving the development of more targeted, lung-specific therapies to address the high unmet need in PH-ILD.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology
As the market is derived using a patient-based model, the PH-ILD epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of ILD, type-specific diagnosed prevalent cases of ILD, type-specific diagnosed prevalent cases of PH-ILD, total diagnosed prevalent cases of PH-ILD, and gender-specific diagnosed prevalent cases of PH-ILD in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
In 2024, in the US, diagnosed prevalence of PH-ILD showed a slightly higher burden in males, with approximately 42,000 cases compared to 39,000 in females. This gender gap is expected to widen by 2034, highlighting potential differences in disease susceptibility or progression.
In 2024, an estimated 69,000 people in the EU4 and the UK were diagnosed with PH-ILD, underscoring a substantial and growing regional disease burden.
In France, CTD linked with PH-ILD had the highest diagnosed prevalence, with nearly 4,000 cases in 2024, while hypersensitivity pneumonitis reported the lowest burden, with just over 500 cases.
In Japan, over 28,000 diagnosed prevalent cases of PH-ILD were reported in 2024, with the numbers projected to increase by 2034, indicating a rising disease burden.
In 2024, IPF accounted for the largest share of PH-ILD cases in Japan at 21%, while hypersensitivity pneumonitis represented just 1%, underscoring notable variation in subtype distribution and the need for tailored diagnostic and treatment strategies.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Drug Chapters
PH-ILD Marketed Drugs
YUTREPIA (Treprostinil): Liquidia Corporation
YUTREPIA is a dry powder inhalation formulation of treprostinil sodium, a prostacyclin mimetic designed for the treatment of PAH. Delivered through a single-use, handheld inhaler, each capsule contains treprostinil sodium blended with carefully selected excipients L-leucine, polysorbate 80, sodium chloride, sodium citrate, and trehalose.
In May 2025, YUTREPIA (treprostinil) received full Food and Drug Administration (FDA) approval for improving exercise capacity in adults with Pulmonary Arterial Hypertension (PAH) and PH-ILD. As the first dry powder prostacyclin using Liquidia’s PRINT technology, it offers deep lung delivery with improved usability and adherence potential.
In August 2024, Liquidia received tentative FDA approval for YUTREPIA, its inhaled dry powder treprostinil for PAH and PH-ILD, with full commercialization allowed after regulatory exclusivity ends in May 2025. The NDA was filed via the 505(b) (2) pathway referencing nebulized TYVASO.
In June 2024, the US District Court denied United Therapeutics’ motion to block YUTREPIA’s launch, removing a key legal hurdle and reinforcing FDA’s ability to advance Liquidia’s amended NDA, strengthening its regulatory and commercial stance.
TYVASO/TYVASO DPI/TREPROST (treprostinil): United Therapeutics
TYVASO and TYVASO DPI (treprostinil) are approved inhaled therapies for PAH (Group 1) and PH-ILD (Group 3), helping improve exercise capacity in adults, though effects may diminish after ~4 hours. In Japan, treprostinil is available as TREPROST, but it has been withdrawn from European markets.
In September 2024, Mochida Pharmaceutical reported that treprostinil had been designated as an Orphan Drug Designation (ODD) from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of PH-ILD, including combined pulmonary fibrosis and emphysema (CPFE). Mochida obtained distribution rights from United Therapeutics in 2017.
In May 2022, the US FDA approved TYVASO DPI inhalation powder, marking the first dry powder inhaler formulation of treprostinil for both PAH (PAH; WHO Group 1) and PH-ILD (PH-ILD; WHO Group 3).
In January 2021, United Therapeutics reported the FDA approval and commercial launch of TYVASO (treprostinil) inhalation aerosol. It is indicated to enhance exercise capacity in patients with PAH and PH-ILD.
PH-ILD Emerging Drugs
Treprostinil liposomal (L606): Pharmosa Biopharm/Liquidia Corporation
L606 is a liposomal formulation of treprostinil, with liposome particle sizes ranging from 110–140 nm, suspended in a sodium citrate–bicarbonate buffer. This advanced formulation is engineered to enhance drug stability and prolong systemic circulation by protecting treprostinil from rapid degradation and clearance. The liposomal encapsulation enables a sustained pulmonary release, allowing for more consistent drug exposure over time, while minimizing peaks and troughs that may lead to side effects. The citrate–bicarbonate buffer not only helps maintain an optimal pH for lung tolerability but also supports better drug solubility and absorption.
In October 2024, Liquidia Corporation and Pharmosa Biopharm (Pharmosa) reported that they have amended the current exclusive licensing agreement for the development and commercialization of L606, an inhaled, sustained-release formulation of treprostinil currently being evaluated in a clinical trial for the treatment of PAH and PH-ILD.
Treprostinil Palmitil Inhalation Powder (TPIP): Insmed
TPIP is a next-generation, once-daily dry powder formulation of a treprostinil prodrug, delivered via a convenient capsule-based inhaler. Engineered by Insmed, TPIP features a 16-carbon ester-linked modification for extended activity and is being developed for PAH, PH-ILD, and other severe pulmonary conditions. With promising Phase IIb results, a pivotal Phase III trial is expected to launch in the second half of 2025, marking a major step toward transforming treatment for rare lung diseases.
Mosliciguat: Roivant Sciences/Pulmovant
Mosliciguat (BAY 1237592) is a first-in-class sGC activator being developed for PH-ILD, offering a nitric oxide–independent mechanism that promotes vasodilation even under hypoxic and oxidative stress conditions. It may also provide anti-inflammatory and anti-fibrotic benefits. Phase II topline results are expected in H2 2026.
In June 2025, Pulmovant reported the publication of Phase I pharmacokinetic data in healthy male volunteers following administration of mosliciguat.
In September 2024, Pulmovant, a Roivant company, reported Phase Ib ATMOS1 study data during the European Respiratory Society (ERS) Congress.
In September 2024, Roivant formed Pulmovant to acquire exclusive global rights from Bayer to develop and commercialize mosliciguat, with Bayer receiving USD 14 million upfront and up to USD 280 million in milestones and tiered royalties. Mosliciguat is being investigated as a once-daily inhaled therapy for PH-ILD.
Drug Class Insights
The PH-ILD treatment landscape is shifting from supportive care to targeted, disease-modifying approaches that address vascular remodeling, fibrosis, and inflammation. Traditional strategies, including ILD management and lung transplantation, offer limited impact on long-term outcomes, highlighting the need for more effective therapies.
New drug classes with lung-targeted mechanisms are advancing PH-ILD treatment. Inhaled prostacyclins like treprostinil have enhanced exercise capacity, setting the stage for next-generation agents such as Mosliciguat (sGC activator), H1614 (HA synthesis inhibitor), and RT234 (inhaled PDE5 inhibitor). These candidates aim to deliver broader benefits—beyond vasodilation—by incorporating anti-fibrotic and anti-inflammatory effects, marking a shift toward disease-modifying approaches.
Continued in report…
Market Outlook
The market for PH-ILD is undergoing significant transformation, driven by growing disease recognition, evolving clinical strategies, and novel therapeutic development. PH-ILD is the most common form of Group 3 pulmonary hypertension and represents a serious complication of ILD, contributing to cardiopulmonary disability, right heart dysfunction, and increased mortality. Despite supportive treatments such as oxygen therapy and corticosteroids to manage acute exacerbations, current standards offer limited long-term benefit and do not halt disease progression.
The introduction of inhaled prostacyclin therapies like TYVASO/ TYVASO DPI, and YUTREPIA—the only agents specifically approved for PH-ILD—has reshaped the therapeutic landscape. These targeted treatments have helped reduce pulmonary vascular resistance (PVR) and improve functional capacity in patients with various for PH-ILD of ILD, including IPF and connective tissue disease-associated ILD. The success of these products has also set the stage for expanding global access and innovation in delivery methods, such as dry powder inhalers and liposomal formulations that enhance patient adherence and convenience.
Real-world studies across the US, Europe, and Japan underscore the high clinical and economic burden of PH-ILD, revealing increased hospitalizations, ICU admissions, and variability in diagnostic and therapeutic approaches. These findings point to underdiagnoses, inconsistent care patterns, and widespread off-label use of pulmonary vasodilators, particularly PDE5 inhibitors, in regions lacking approved therapies. They also emphasize the urgent need for standardized, evidence-based guidelines and more effective, accessible treatments.
The pipeline for PH-ILD is rich with candidates targeting not just vasodilation, but also fibrosis and vascular remodeling—key PH-ILD driving disease progression. Inhaled agents like TPIP, mosliciguat, seralutinib, and RT234, and oral therapies like H1614, represent next-generation approaches aiming to offer improved efficacy, safety, and disease-modifying potential. Many of these are in Phase II or III development and could transform management by offering alternatives to current standards or enhancing outcomes through combination strategies.
With rising transplant volumes, increased disease awareness, and strong momentum in clinical research, the PH-ILD therapeutics market is poised for sustained growth from 2025 to 2034. As more targeted agents gain approval and are integrated into practice, PH-ILD management is expected to shift toward a more personalized, mechanism-driven approach ultimately improving prognosis and quality of life for patients facing this progressive condition.
Companies like United Therapeutics (TYVASO/TYVASO DPI/ TREPROST), Liquidia Corporation (YUTREPIA), Bayer (Mosliciguat), Halo Biosciences (H1614), and other are actively advancing therapies for PH-ILD, with assets spanning late-stage (Phase III) to early-stage (Phase I) development. These program PH-ILD reflect a strategic industry focus on inhaled and lung-specific PH-ILD targeting vasodilation, fibrosis, and inflammation—key drivers of disease progression in PH-ILD.
The total market size of PH-ILD in the 7MM was approximately USD 3 billion in 2024 and is projected to increase during the forecast period (2025–2034).
The market size for PH-ILD in the US was approximately USD 2 billion in 2024 and is anticipated to increase due to the launch of emerging therapies.
The total market size of EU4 and the UK was calculated to be approximately USD 480 million in 2024, which was nearly 23% of the total market revenue for the 7MM and is expected to increase by 2034.
In 2024, the UK dominated the European market, generating around USD 120 million. Germany followed closely with approximately USD 100 million, while Spain recorded around USD 70 million.
In 2024, the total market size of PH-ILD was approximately USD 285 million in Japan, which is anticipated to increase during the forecast period (2025-2034).
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to be launched in the market during study period 2020–2034.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.
Pipeline development activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for PH-ILD.
KOL Views
To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on PH-ILD evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and others.
DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the Baylor College of Medicine and Methodist Hospital, US; University of Minnesota, US; University of Freiburg, Germany; Hôpital St Louis, France; University of Siena, Italy; University of Valencia, Spain; University Forvie Site, UK; Jichi Medical University, Japan; and Chiba University, Japan; among others, were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or PH-ILD market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Physician’s View
KOLs in the US highlight a critical gap in PH-ILD care, noting that despite rising prevalence, timely diagnosis remains low due to overlapping symptoms of PH-ILD with other ILDs. This diagnostic delay often results in patients missing the optimal treatment window for slowing disease progression.
According to European KOLs, current treatment options for PH-ILD remain largely supportive, with few therapies targeting the underlying vascular remodeling and fibrotic processes. This underscores an urgent need for more effective, disease-modifying interventions.
Japanese KOLs stress the growing burden of PH-ILD, particularly among aging ILD populations, and emphasize that limited approved therapies fail to address the heterogeneity of the disease. The lack of standardized treatment protocols further contributes to unmet needs in real-world clinical management.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Attribute Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in PH-ILD of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Attribute Analysis analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies’ safety is evaluated wherein the adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials, which directly affects the safety of the molecule in the upcoming trials. It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
US
YUTREPIA: Liquidia Corporation
VOUCHER PROGRAM
The YUTREPIA Voucher Program offers a one-time, 28-day supply of the therapy at no cost to eligible patients, providing a critical opportunity to assess tolerability, adherence, and clinical fit before initiating full treatment. This approach not only reduces financial hesitation at the start of care but also supports informed decision-making for both patients and providers, ultimately promoting sustained engagement with therapy and optimizing long-term treatment outcomes.
Patient eligible
Patients may be eligible for the YUTREPIA Voucher Program if they have been prescribed YUTREPIA for an FDA-approved indication and are 18 years of age or older, or if under 18, are enrolled by their legal guardian(s). This eligibility framework ensures appropriate access while supporting early evaluation of the therapy in alignment with regulatory and clinical standards.
Further details will be provided in the report.
The report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios, PH-ILD making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug PH-ILD, etc.
Scope of the Report
The report covers a segment of key events, an executive summary, and a descriptive overview of PH-ILD, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.
Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will affect the current treatment landscape.
A detailed review of the PH-ILD market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM PH-ILD market.
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Report Insights
Patient Population
Therapeutic Approaches
PH-ILD Pipeline Analysis
PH-ILD Market Size and Trends
Existing and Future Market Opportunity
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Report Key Strengths
10 years Forecast
The 7MM Coverage
PH-ILD Epidemiology Segmentation
Key Cross Competition
Attribute analysis
Drugs Uptake and Key Market Forecast Assumptions
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Qualitative Analysis (SWOT and Attribute Analysis)
Key Questions
Market Insights
What was the total market size of PH-ILD, the market size of PH-ILD by therapies, and market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for this growth?
How will Treprostinil liposomal (L606) affect the treatment paradigm of PH-ILD?
Which drug is going to be the largest contributor by 2034?
What are the pricing variations among different geographies for approved and marketed therapies?
How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of PH-ILD? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PH-ILD?
What is the historical and forecasted PH-ILD patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
Out of the countries mentioned above, which country would have the highest diagnosed prevalent PH-ILD population during the forecast period (2025–2034)?
What factors are contributing to the growth of PH-ILD cases?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
What are the current options for the treatment of PH-ILD? What are the current clinical and treatment guidelines for treating PH-ILD?
How many companies are developing therapies for the treatment of PH-ILD?
How many emerging therapies are in the mid-stage and late stage of development for treating PH-ILD?
What are the recent novel therapies, targets, PH-ILD of action, and technologies developed to overcome the limitations of existing therapies?
Patient acceptability in PH-ILD of preferred treatment options as per real-world scenarios?
What is the 7MM historical and forecasted market of PH-ILD?
Reasons to Buy
The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the PH-ILD market.
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
The distribution of historical and current patient share is based on real-world prescription data in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Identifying upcoming solid players in the market will help devise strategies to help get ahead of competitors.
Detailed analysis, ranking of class-wise potential current, and emerging therapies under the attribute analysis section to provide visibility around leading classes.
Highlights of Access and Reimbursement policies for PH-ILD, barriers to accessibility of approved therapy, and patient assistance PH-ILD.
To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
Table of Contents
190 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. PH-ILD Market Overview at a Glance
- 3.1. Market Share (%) Distribution of PH-ILD by Therapies in the 7MM in 2024
- 3.2. Market Share (%) Distribution of PH-ILD by Therapies in the 7MM in 2034
- 4. Executive Summary
- 5. Key Events
- 6. Disease Background and Overview
- 6.1. Introduction
- 6.2. Classification
- 6.3. Clinical Manifestations
- 6.4. Risk Factors
- 6.5. Pathogenesis
- 6.6. Recurrent PH-ILD
- 6.7. Biomarkers
- 6.8. Diagnosis
- 6.8.1. Differential Diagnosis
- 6.8.2. Diagnostic Algorithm
- 6.8.3. Diagnostic Guidelines and Recommendations
- 6.9. Treatment and Management
- 6.9.1. Treatment Algorithm
- 6.9.2. Treatment Guidelines and Recommendations
- 7. Methodology
- 8. Epidemiology and Patient Population
- 8.1. Key Findings
- 8.2. Assumptions and Rationale: The 7MM
- 8.2.1. Total Diagnosed Prevalent Cases of ILD
- 8.2.2. Type-specific Diagnosed Prevalent Cases of ILD
- 8.2.3. Type-specific Diagnosed Prevalent Cases of PH-ILD
- 8.2.4. Total Diagnosed Prevalent Cases of PH-ILD
- 8.2.5. Gender-specific Diagnosed Prevalent Cases of PH-ILD
- 8.3. Total Diagnosed Prevalent Cases of PH-ILD in the 7MM
- 8.4. The US
- 8.4.1. Total Diagnosed Prevalent Cases of ILD
- 8.4.2. Type-specific Diagnosed Prevalent Cases of ILD
- 8.4.3. Type-specific Diagnosed Prevalent Cases of PH-ILD
- 8.4.4. Total Diagnosed Prevalent Cases of PH-ILD
- 8.4.5. Gender-specific Diagnosed Prevalent Cases of PH-ILD
- 8.5. EU4 and the UK
- 8.5.1. Total Diagnosed Prevalent Cases of ILD
- 8.5.2. Type-specific Diagnosed Prevalent Cases of ILD
- 8.5.3. Type-specific Diagnosed Prevalent Cases of PH-ILD
- 8.5.4. Total Diagnosed Prevalent Cases of PH-ILD
- 8.5.5. Gender-specific Diagnosed Prevalent Cases of PH-ILD
- 8.6. Japan
- 8.6.1. Total Diagnosed Prevalent Cases of ILD
- 8.6.2. Type-specific Diagnosed Prevalent Cases of ILD
- 8.6.3. Type-specific Diagnosed Prevalent Cases of PH-ILD
- 8.6.4. Total Diagnosed Prevalent Cases of PH-ILD
- 8.6.5. Gender-specific Diagnosed Prevalent Cases of PH-ILD
- 9. Patient Journey
- 10. Marketed Drugs
- 10.1. Key Cross Competition
- 10.2. YUTREPIA (Treprostinil): Liquidia Corporation
- 10.2.1. Product Description
- 10.2.2. Regulatory Milestones
- 10.2.3. Other Developmental Activities
- 10.2.4. Clinical Trials Information
- 10.2.5. Safety and Efficacy
- 10.3. TYVASO/TYVASO DPI/ TREPROST (Treprostinil): United Therapeutics
- 10.3.1. Product Description
- 10.3.2. Regulatory Milestones
- 10.3.3. Other Developmental Activities
- 10.3.4. Clinical Trials Information
- 10.3.5. Safety and Efficacy
- List to be continued in the final report.
- 11. Emerging Drugs
- 11.1. Key Cross Competition
- 11.2. Treprostinil liposomal (L606): Pharmosa BioPharm/ Liquidia Corporation
- 11.2.1. Drug Description
- 11.2.2. Other Developmental Activities
- 11.2.3. Clinical Trials Information
- 11.2.4. Safety and Efficacy
- 11.2.5. Analysts’ View
- 11.3. Treprostinil Palmitil Inhalation Powder (TPIP): Insmed
- 11.3.1. Drug Description
- 11.3.2. Other Developmental Activities
- 11.3.3. Clinical Trials Information
- 11.3.4. Safety and Efficacy
- 11.3.5. Analysts’ View
- 11.4. Mosliciguat: Roivant Sciences/Pulmovant
- 11.4.1. Drug Description
- 11.4.2. Other Developmental Activities
- 11.4.3. Clinical Trials Information
- 11.4.4. Safety and Efficacy
- 11.4.5. Analysts’ View
- List to be continued in the final report.
- 12. PH-ILD – 7MM Market Analysis
- 12.1. Key Findings
- 12.2. Key Market Forecast Assumptions
- 12.2.1. Cost Assumptions and Rebates
- 12.2.2. Pricing Trends
- 12.2.3. Analogue Assessment
- 12.2.4. Launch Year and Therapy Uptake
- 12.3. Market Outlook
- 12.4. Attribute Analysis
- 12.5. Total Market Size of PH-ILD in the 7MM
- 12.6. Market Size of PH-ILD by Therapies in the 7MM
- 12.7. Market Size of PH-ILD in the United States
- 12.7.1. Total Market Size of PH-ILD
- 12.7.2. Market Size of PH-ILD by Therapies in the United States
- 12.8. Market Size of PH-ILD in EU4 and the UK
- 12.8.1. Total Market Size of PH-ILD
- 12.8.2. Market Size of PH-ILD by Therapies in EU4 and the UK
- 12.9. Market Size of PH-ILD in Japan
- 12.9.1. Total Market Size of PH-ILD
- 12.9.2. Market Size of PH-ILD by Therapies in Japan
- 13. KOL Views
- 14. Unmet Needs
- 15. SWOT Analysis
- 16. Market Access and Reimbursement
- 16.1. The United States
- 16.1.1. CMS
- 16.2. In EU4 and the UK
- 16.2.1. Germany
- 16.2.2. France
- 16.2.3. Italy
- 16.2.4. Spain
- 16.2.5. The United Kingdom
- 16.3. Japan
- 16.3.1. MHLW
- 17. Appendix
- 17.1. Acrony and Abbreviations
- 17.2. Bibliography
- 17.3. Report Methodology
- 18. DelveInsight Capabilities
- 19. Disclaimer
- 20. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
